Australia markets closed

Boston Scientific Corporation (BSX)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
76.31+0.12 (+0.16%)
At close: 04:00PM EDT
76.05 -0.26 (-0.34%)
Pre-market: 05:39AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close76.19
Open76.13
Bid75.89 x 900
Ask0.00 x 900
Day's range75.38 - 76.49
52-week range48.35 - 77.64
Volume5,361,142
Avg. volume5,841,091
Market cap112.189B
Beta (5Y monthly)0.81
PE ratio (TTM)64.13
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific

    Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (“Boston Scientific”) (NYSE: BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity valu

  • PR Newswire

    Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc.

    Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 per share, reflecting an enterprise value of approximately $1.16 billion.i

  • PR Newswire

    MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints

    Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP). As components of the mCRM System, the devices are designed to work together wirelessly to coordinate painless intracardiac anti-tachycardia pacing (ATP) therap